Gyre Therapeutics, Inc.GYRENASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank86
3Y CAGR+4.1%
5Y CAGR+7.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+4.1%/yr
vs +27.1%/yr prior
5Y CAGR
+7.6%/yr
Recent deceleration
Acceleration
-23.0pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $99.69M | +16.3% |
| 2024 | $85.71M | -51.3% |
| 2023 | $176.04M | +99.4% |
| 2022 | $88.29M | +5.9% |
| 2021 | $83.39M | +20.6% |
| 2020 | $69.16M | +21.0% |
| 2019 | $57.13M | +68.9% |
| 2018 | $33.83M | +48.1% |
| 2017 | $22.84M | +9.7% |
| 2016 | $20.82M | - |